Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Carboplatin + HB-201 + HB-202 + Paclitaxel|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Carboplatin||Paraplatin||CBDCA||Chemotherapy - Platinum 7||Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary).|
|HB-201||HB201|HB 201|HPV E6/E7-encoding arenavirus vaccine HB-201||HB-201 consists of lymphocytic choriomeningitis virus that is engineered to express an HPV16-derived E6/E7 fusion protein, which potentially induces host immune response, thereby resulting in the lysis of HPV16 E6 and E7-expressing tumor cells (NCI Drug Dictionary).|
|HB-202||HB202|HB 202||HB-202 is a replication-defective arenavirus-based cancer vaccine that expresses an HPV16-derived E6/E7 fusion protein, which potentially induces host immune response, thereby resulting in the lysis of HPV16 E6 and E7-expressing tumor cells (NCI Drug Dictionary).|
|Paclitaxel||Taxol||7-Epipaclitaxel||Antimicrotubule Agent 14 BCL2 Family Inhibitor 6||Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT05108870||Phase Ib/II||Carboplatin + HB-201 + Paclitaxel Carboplatin + HB-201 + HB-202 + Paclitaxel||TheraT Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers||Recruiting||USA||0|